CN108514639A - It is a kind of to be used for antitumor combination medicine and its preparation and application - Google Patents
It is a kind of to be used for antitumor combination medicine and its preparation and application Download PDFInfo
- Publication number
- CN108514639A CN108514639A CN201810387270.0A CN201810387270A CN108514639A CN 108514639 A CN108514639 A CN 108514639A CN 201810387270 A CN201810387270 A CN 201810387270A CN 108514639 A CN108514639 A CN 108514639A
- Authority
- CN
- China
- Prior art keywords
- combination medicine
- disulfiram
- cancer
- preparation
- class compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims abstract description 77
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 68
- 229960002563 disulfiram Drugs 0.000 claims abstract description 38
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims abstract description 21
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 21
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims abstract description 20
- -1 angiogenesis inhibitor class compound Chemical class 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 claims description 11
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims description 11
- 229950009003 cilengitide Drugs 0.000 claims description 11
- 229950002189 enzastaurin Drugs 0.000 claims description 11
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 10
- 229960005167 everolimus Drugs 0.000 claims description 10
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 9
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 9
- 229940034785 sutent Drugs 0.000 claims description 9
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 6
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229960002448 dasatinib Drugs 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 229960003787 sorafenib Drugs 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 201000001531 bladder carcinoma Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 3
- 239000002122 magnetic nanoparticle Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 32
- 238000011160 research Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002075 anti-alcohol Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000940 tivozanib Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940016468 combination disulfiram Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It being used for antitumor combination medicine and its preparation and application the present invention relates to a kind of, the combination medicine to include angiogenesis inhibitor class compound and disulfiram, and the weight proportion of the angiogenesis inhibitor class compound and disulfiram is：(1‑15):(1‑20).When angiogenesis inhibitor class compound is combined disulfiram medication by the present invention, compared with its any type independent medication, have the function of significantly improving anticancer effect.And tumour inhibiting rate improves 20% or more, which belongs to great progress in the research for the treatment of cancer.The applicant studies for the first time is found that angiogenesis inhibitor is significant synergistic with the use of having the function of under specific proportioning with disulfiram, and potential applicability in clinical practice is good.
Description
Technical field
The present invention relates to pharmaceutical technology fields, and in particular to a kind of novel to be used for antitumor combination medicine and the joint
The application of drug.
Background technology
Studies have shown that there are two types of the supply blood vessel generation mechanisms that tumour growth is relied on：1, tumour is by secreted by itself
Cell factor, the normal blood vessels closed on can be stimulated to generate branch vessel, supplied to itself；2, tumor tissues are first at itself
Inside generates blood vessel sample as a result, then " grafting " on the normal blood vessels closed on.The two mechanism is essentially different, simply
For, the sequencing of inside and outside vascularization is different.The similar part of the two is then to be required for generating capillary structure, this
The main reason that the speciality of DIY, exactly anti-angiogenic medicaments can act.
Although anti-cell proliferation agents can kill tumour cell, due to the support of peripheral vessels, residual tumor cell
It still can get blood supply and be able to continued growth.Meanwhile abnormal tumor vessel makes drug be reduced to tumor tissues internal delivery, most
The effect of causing suppressing cell reproduction to be treated eventually, is limited.In recent years, researcher proposes new tumor pharmacother strategy, not only needle
To tumour cell, it to be more directed to tumor microenvironment, especially Tumor Angiongesis, hits tumour in all directions.With act only on
The chemotherapeutics of tumor cell proliferation is different, by being specifically bound with VEGF, prevents itself and acceptor interaction, plays to swollen
A variety of effects of tumor blood vessel：Existing tumor vessel is set to degenerate, to cut off oxygen needed for growth of tumour cell and other nutrition
Substance；Make the tumor vessel normalization of survival, pressed between reduction tumor tissues, improves transmission of the chemotherapeutics into tumor tissues,
Improve chemotherapy effect；Inhibit tumor angiogenesis, to persistently inhibit the growth and transfer of tumour cell.
However, Antineoplastic angiogenesis treatment result in the clinical research of other tumours is splendid, but in Treatment for Glioma
The effect of aspect is not satisfied；Including bevacizumab blocking VEGF, cilengitide inhibits integrin, Sutent or Si Dinibu
Inhibit vegf receptor, Imatinib or Dasatinib inhibit PDGFR, Enzastaurin (Enzastaurin) inhibit protein kinase C and
Rapamycin, everolimus or tesirolimus inhibit mTOR, cannot explain well this phenomenon at present.
Last century mid-term, the Erik Jacobsen of University of Copenhagen have found that disulfiram inhibits when studying disulfiram
Particularly important acetaldehyde dehydrogenase during alcohol metabolism causes the acetaldehyde that alcohol metabolism generates largely to be accumulated in human body,
Then there is the reaction of similar alcoholism.Under the effort of Jacobsen, disulfiram has been developed to a Temperance medicine.Closely
Since 20 years, the counteroffensive again of antialcoholic disulfiram is multiple the study found that disulfiram has antitumaous effect unexpectedly, can kill
The kinds of tumor cells such as breast cancer, prostate cancer.And up to more than 60 years " antialcoholic history ", it was demonstrated that disulfiram is fool proof,
Its side effect is much smaller compared to for the chemotherapeutics of most of tumours.
Angiogenesis inhibitor combination disulfiram application is effectively increased combination medicine anti-by the present invention significantly
Therapeutic effect in tumour medicine expands therapeutic domain of the combination medicine in antitumor, can substantially reduce controlling for patient
Treatment expense, with market potential value and far-reaching social effect.
Invention content
The object of the present invention is to provide a kind of for antitumor combination medicine and its preparation and application, existing to overcome
The deficiency mentioned in technology.The purpose of the present invention is be achieved through the following technical solutions：
It is a kind of be used for antitumor combination medicine, the combination medicine include angiogenesis inhibitor class compound and
The weight proportion of disulfiram, the angiogenesis inhibitor class compound and disulfiram is：(1-15):(1-20).
Further, the weight proportion of the angiogenesis inhibitor class compound and disulfiram is：1:(4-10).
Further, the angiogenesis inhibitor class compound include but not limited to Sutent, Si Dinibu,
Sorafenib, Tivozanib (replace Wo Zhani), cilengitide, Imatinib, Dasatinib, Enzastaurin, rapamycin, according to
At least one of Wei Mosi and tesirolimus.
Further, the combination medicine further includes at least one pharmaceutically acceptable carrier.
Further, the pharmaceutically acceptable carrier includes but not limited to liposome, polymer nanoparticle and magnetism
At least one of nanoparticle, dosage are 5~50 times of combination medicine weight.
Further, the angiogenesis inhibitor class compound includes Si Dinibu, Sorafenib, is pricked for fertile
It is one or two kinds of in Buddhist nun, cilengitide, Dasatinib, Enzastaurin and everolimus.
A kind of to be used for antitumor combination medicine as the preparation of active ingredient using described, the preparation includes solid pharmaceutical preparation
And injection.The solid pharmaceutical preparation includes but not limited to tablet, capsule, pill, micropill preparation.
Application of the combination medicine in the drug for preparing treating cancer described in a kind of, the cancer includes but not limited to liver
Cancer, kidney, breast cancer, colon cancer, nasopharyngeal carcinoma, carcinoma of urinary bladder, gastric cancer, cancer of the esophagus, prostate cancer, leukaemia, malignant mela noma
And lymthoma.
Beneficial effects of the present invention are：
It being used for antitumor combination medicine and its preparation and application the present invention provides a kind of, the present invention to be by tumor vessel
It is anti-with significantly improving compared with its any type independent medication when formation inhibitor class compound combines disulfiram medication
The effect of cancer effect.And tumour inhibiting rate improves 20% or more, which belongs to great progress in the research for the treatment of cancer.
The applicant studies for the first time is found that angiogenesis inhibitor is notable with the use of having under specific proportioning with disulfiram
Synergistic effect, potential applicability in clinical practice is good.In addition, applicant have also found that, 2 kinds of certain Tumor Angiongesis are pressed down
When preparation is used in combination with disulfiram, moreover it is possible to further increase tumor killing effect, therefore there is extremely important potential applicability in clinical practice.
Specific implementation mode
Illustrate specific implementation mode by taking specific experiment case as an example below, it should be understood that specific reality described herein
It applies example to be only used to explain the present invention, be not intended to limit the present invention.
Embodiment 1
It is a kind of be used for antitumor combination medicine, the combination medicine include angiogenesis inhibitor class compound and
The weight proportion of disulfiram, the angiogenesis inhibitor class compound and disulfiram is：(1-15):(1-20), such as 1:1、
1:5、1:7.5、1:10、1:15、1:20、5:1、10:1 or 15:1 etc.；It is preferred that 1:(4-10).
The angiogenesis inhibitor class compound include but not limited to Sutent, Si Dinibu, Sorafenib,
Tivozanib (replace Wo Zhani), cilengitide, Imatinib, Dasatinib, Enzastaurin, rapamycin, everolimus and
At least one of tesirolimus.
As further preferred embodiment, the combination medicine further includes at least one pharmaceutically acceptable load
Body.The pharmaceutically acceptable carrier includes but not limited at least one in liposome, polymer nanoparticle and magnetic nano particle
Kind, dosage is 5~50 times of combination medicine weight, such as 10 times or 20 times.
Drug in the present embodiment by two class drug synergisms, can effectively treat liver cancer, kidney, breast cancer,
Colon cancer, nasopharyngeal carcinoma, carcinoma of urinary bladder, gastric cancer, cancer of the esophagus, prostate cancer, leukaemia, malignant mela noma and lymthoma etc..
Embodiment 2
The preparation method for antitumor combination medicine in embodiment 1 is：Disulfiram powder and tumor vessel are given birth to
It is mixed in proportion at inhibitor type compound powder.
The combination medicine can be made into solid pharmaceutical preparation or injection, but active ingredient is consistent described in embodiment 1, is
Including angiogenesis inhibitor class compound and disulfiram, carrier can also be added；Solid pharmaceutical preparation includes tablet, capsule, ball
Agent, micropill preparation etc., specific preparation method referring to corresponding dosage form in the prior art preparation method.
Embodiment 3
Angiogenesis inhibitor class compound and disulfiram are pressed 1:7 be used as experimental group, using common pure water as
Contrast groups.
Experimental subjects：Healthy mice 10, every group 5,19 ± 1g of average weight, animal subject is through medical fitness.
Contrast groups are gavaged into pure water, the combination medicine in experimental group is pressed into each 3mL respectively, gavages mouse 3 times a day,
It is observed continuously 10 days, claims its weight, observation vigor situation, as a result, it has been found that, the weight of all mouse in experimental group and contrast groups
It is substantially unchanged with vigor, therefore the toxic side effect of the drug combination in the present invention is smaller or does not have.
Embodiment 4
1 experiment material
1.1 experimental animals and observation
Balb/c mouse, 10~12 week old, 21~23g of weight, half male and half female, by the limited public affairs of Wuhan Hua Lian section biotechnology
Department provides.Hubei University Of Technology's bioengineering and Foodstuffs Academy animal observation ward.
1.2 tumor tissues
Mouse Renca renal cancer tumor tissues, are provided by Biochemical Lab of Hubei University Of Technology.
1.3 experimental drug
1. angiogenesis inhibitor：It is provided, is set by Wuhan Mai Desen medical sci-teches limited liability company for Wo Zhani
It is preserved in -20 DEG C of refrigerators；Other angiogenesis inhibitors are provided by hospital of Tongji University of the Central China University of Science and Technology, and -10 DEG C of refrigerators are protected
It deposits.2. disulfiram：The Suzhou bio tech ltd Fu Lu, room temperature preserve.
1.4 laboratory apparatus
A ten thousandth assay balance, Beijing Sai Duolisi instrument systems Co., Ltd；The phases such as operating scissors, surgical clamp, tweezers
Surgical instrument is closed, (120 DEG C, 20min) are sterilized through excessively high Warm using preceding.
2 experimental methods
It is prepared by 2.1 lotus knurl kind mouse
Renca renal carcinoma tissues are taken out from liquid nitrogen, 37 DEG C of rapid defrostings adjust concentration to 1 × 108A/ml for
Injection.10 Balb/c mouse are taken, by 5 × 106A (0.2ml) Renca kidney cancer cells are inoculated in every mouse and cover lower skin, make
It is spare for kind of mouse.
It is prepared by 2.2Renca renal carcinoma models
Renca cells are with 5 × 108A/L is suspended in serum-free RPMI 1640 culture mediums, through the right lateral side of femur skin of mouse
Balb/c tumor-bearing mices are put to death after lower injection 0.1ml, inoculated tumour cell 5d, tumor tissue are stripped under aseptic condition, by tumour
Matter (g) is with physiological saline (ml) according to 1:Prepared by the homogenate of 3 ratios become suspension, and every mouse is inoculated in left armpit according to 0.2ml
Lower skin.
2.3 animal packets and administration
Next day is randomly divided into 4 groups according to weight after mouse inoculation tumour cell, every group 10 i.e. model group (0.5%CMC-
Na solution), angiogenesis inhibitor group, disulfiram group, combination medicine group.Dosage and mode are shown in Table 1.
1 experimental drug dosage regimen of table
Note：Ig indicates gastric infusion；Q.d. it indicates once a day.
The measurement of 2.4 tumour inhibiting rates
By Dosage Regimens Dosage.15d puts to death mouse, and tumor tissues is taken to claim knurl weight, calculates tumour inhibiting rate.
Average knurl weight × 100% of tumour inhibiting rate (%)=(average knurl weight of model group-treatment group's average knurl weight)/model group
2.5 statistical method
Data are indicated using " mean+standard deviation " (X ± SD), are analyzed using SPSS19.0 statistical softwares, variance is neat
It is examined using T, those who do not meet are analyzed using non-parametric test method.
3 experimental results
3.1 tumour inhibiting rate measurement results
When angiogenesis inhibitor is for Wo Zhani, tumour inhibiting rate measurement result is as shown in table 2.
Influence of the table 2 to Balb/c kidney tumor-bearing mice tumour inhibiting rates
Note：Compared with model control group：*P<0.05, * * P<0.01.
3.2 tumour inhibiting rate measurement results
When angiogenesis inhibitor is Si Dinibu, tumour inhibiting rate measurement result is as shown in table 3.
Influence of the table 3 to Balb/c kidney tumor-bearing mice tumour inhibiting rates
Note：Compared with model control group：*P<0.05, * * P<0.01.
3.3 tumour inhibiting rate measurement results
When angiogenesis inhibitor is Sutent, tumour inhibiting rate measurement result is as shown in table 4.
Influence of the table 4 to Balb/c kidney tumor-bearing mice tumour inhibiting rates
Note：Compared with model control group：*P<0.05, * * P<0.01.
3.4 tumour inhibiting rate measurement results
When angiogenesis inhibitor is everolimus, tumour inhibiting rate measurement result is as shown in table 5.
Influence of the table 5 to Balb/c kidney tumor-bearing mice tumour inhibiting rates
Note：Compared with model control group：*P<0.05, * * P<0.01.
3.5 tumour inhibiting rate measurement results
When angiogenesis inhibitor is tesirolimus, tumour inhibiting rate measurement result is as shown in table 6.
Influence of the table 6 to Balb/c kidney tumor-bearing mice tumour inhibiting rates
Note：Compared with model control group：*P<0.05, * * P<0.01.
From 3.1-3.5：For Wo Zhani, Si Dinibu, Sutent, everolimus or tesirolimus (2mg/kg)
It, can substantially reduced knurl weight (p after 10d is administered in continuous gavage<0.05), tumour inhibiting rate shows 2mg/kg agent between 36-39.2%
Amount has preferable inhibition Renca tumours life for Wo Zhani, Si Dinibu, Sutent, everolimus or tesirolimus
Long effect.
After 10d is administered in disulfiram (250mg/kg) continuous gavage, there is apparent tumor-inhibiting action (P<0.05), tumour inhibiting rate is
29.39%, show that the disulfiram of 15mg/kg dosage has the function of preferably inhibiting Renca tumour growths.
(combine when Wo Zhani, Si Dinibu, Sutent, everolimus or tesirolimus joint disulfiram will be replaced
Drug, wherein angiogenesis inhibitor 2mg/kg and disulfiram 15mg/kg) continuous gavage administration 10d after, can show very much
It writes and mitigates knurl weight (p<0.01), inhibitory rate has arrived 56-58%, and tumour inhibiting rate is used alone apparent than angiogenesis inhibitor
20% or so is improved, increase rate is high；The tumour inhibiting rate of combination medicine improves 26-30% than disulfiram exclusive use, improves
Rate is high.It follows that when angiogenesis inhibitor combines disulfiram medication, there is extraordinary inhibition Renca tumours
The effect of growth.
The above result shows that：For Wo Zhani, Si Dinibu, Sutent, everolimus or tesirolimus and disulfiram
Have the effect for the treatment of tumour when exclusive use, illustrates that there is synergy after the two is used cooperatively under the specific proportioning of the present invention
Effect, potential applicability in clinical practice is good.
3.6 tumour inhibiting rate measurement results
When angiogenesis inhibitor is other one or more, tumour inhibiting rate measurement result is as shown in table 7.
Influence of the table 7 to Balb/c kidney tumor-bearing mice tumour inhibiting rates
Note：Compared with model control group：*P<0.05, * * P<0.01.
The applicant is used cooperatively by using angiogenesis inhibitor of more than two kinds with disulfiram, as above
Shown in table 7, as a result, it has been found that, combine cilengitide in use, its tumor suppression using two kinds of angiogenesis inhibitor Enzastaurins
It is slightly improved when rate is used alone than a kind of angiogenesis inhibitor, has reached 41.33%, increase rate unobvious；However
(Enzastaurin 1mg/kg, cilengitide 1mg/kg, disulfiram is used in combination with disulfiram in Enzastaurin and cilengitide
15mg/kg), it is used in combination with disulfiram than a kind of angiogenesis inhibitor or two kinds of angiogenesis inhibitors
It is used in combination, tumour inhibiting rate all greatly improves, and has reached 66.63%, and the applicant is in order to verify whether it is that rear period error is led
It causes, has also further done multiple repetitions and tested, as a result, it has been found that, each result uses other kinds of 2 65% or more
Kind or more angiogenesis inhibitor and disulfiram be used cooperatively (some, which are combined, is not embodied in table 7), result
It is a kind of almost the same with only using.And Enzastaurin and cilengitide are used in combination the applicant, as a result, it has been found that its tumour inhibiting rate
Than floating there is no apparent.Thus it can further illustrate, by Enzastaurin and cilengitide and disulfiram use in conjunction, have bright
Aobvious synergistic function.
The present invention is not limited to above-mentioned preferred forms, anyone can show that other are various under the inspiration of the present invention
The product of form, however, make any variation in its shape or structure, it is every that there is skill identical or similar to the present application
Art scheme, is within the scope of the present invention.
Claims (10)
1. a kind of being used for antitumor combination medicine, it is characterised in that：The combination medicine includes angiogenesis inhibitor
The weight proportion of class compound and disulfiram, the angiogenesis inhibitor class compound and disulfiram is：(1-15):(1-
20)。
2. according to claim 1 be used for antitumor combination medicine, it is characterised in that：The Tumor Angiongesis inhibits
The weight proportion of agent class compound and disulfiram is：1:(4-10).
3. according to claim 2 be used for antitumor combination medicine, it is characterised in that：The Tumor Angiongesis inhibits
Agent class compound include but not limited to Sutent, Si Dinibu, Sorafenib, for Wo Zhani, cilengitide, Imatinib,
At least one of Dasatinib, Enzastaurin, rapamycin, everolimus and tesirolimus.
4. according to claim 3 be used for antitumor combination medicine, it is characterised in that：The combination medicine further include to
A kind of few pharmaceutically acceptable carrier.
5. according to claim 4 be used for antitumor combination medicine, it is characterised in that：The pharmaceutically acceptable load
The dosage of body is 5~50 times of combination medicine weight.
6. according to claim 5 be used for antitumor combination medicine, it is characterised in that：The pharmaceutically acceptable load
Body includes but not limited at least one of liposome, polymer nanoparticle and magnetic nano particle.
7. according to claim 4 be used for antitumor combination medicine, it is characterised in that：The Tumor Angiongesis inhibits
Agent class compound includes Si Dinibu, Sorafenib, replaces Wo Zhani, cilengitide, Dasatinib, Enzastaurin and everolimus
Middle one or two.
8. it is a kind of using described in any one of claim 1-7 for antitumor combination medicine as the preparation of active ingredient,
It is characterized in that：The preparation includes solid pharmaceutical preparation and injection.
9. the preparation according to claim 8 for antitumor combination medicine, it is characterised in that：The solid pharmaceutical preparation packet
Include but be not limited to tablet, capsule, pill, micropill preparation.
10. a kind of application of claim 1-7 any one of them combination medicines in the drug for being used to prepare treating cancer,
It is characterized in that, the cancer includes but not limited to liver cancer, kidney, breast cancer, colon cancer, nasopharyngeal carcinoma, carcinoma of urinary bladder, gastric cancer, esophagus
Cancer, prostate cancer, leukaemia, malignant mela noma and lymthoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810387270.0A CN108514639A (en) | 2018-04-26 | 2018-04-26 | It is a kind of to be used for antitumor combination medicine and its preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810387270.0A CN108514639A (en) | 2018-04-26 | 2018-04-26 | It is a kind of to be used for antitumor combination medicine and its preparation and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108514639A true CN108514639A (en) | 2018-09-11 |
Family
ID=63429118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810387270.0A Pending CN108514639A (en) | 2018-04-26 | 2018-04-26 | It is a kind of to be used for antitumor combination medicine and its preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108514639A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111803477A (en) * | 2020-08-11 | 2020-10-23 | 上海交通大学 | The use of disulfiram in the preparation of anti-head and neck cancer and anti-fibrosis drugs |
| CN114146073A (en) * | 2020-09-07 | 2022-03-08 | 上海交通大学医学院 | Application of disulfiram in enhancing immune response |
| CN114366749A (en) * | 2020-10-15 | 2022-04-19 | 中国人民解放军海军军医大学 | Use of integrin inhibitor in preparation of medicament for treating renal cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100099757A1 (en) * | 2006-12-04 | 2010-04-22 | Yossef Israeli-Shalev | Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders |
| CN102357100A (en) * | 2011-10-12 | 2012-02-22 | 沈阳药科大学 | Anti-tumor combination medicament |
-
2018
- 2018-04-26 CN CN201810387270.0A patent/CN108514639A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100099757A1 (en) * | 2006-12-04 | 2010-04-22 | Yossef Israeli-Shalev | Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders |
| CN102357100A (en) * | 2011-10-12 | 2012-02-22 | 沈阳药科大学 | Anti-tumor combination medicament |
Non-Patent Citations (3)
| Title |
|---|
| KIRSI KETOLA ETAL.: "Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in ProstateCancer Cells", 《PLOS ONE》 * |
| ZHIPENG WANG ETAL.: "Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells", 《NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE》 * |
| 赵鹏飞: "肿瘤细胞和Ｍ２型巨噬细胞双靶向的白蛋白纳米载药系统治疗耐药结肠癌的研究", 《中国优秀硕士学位论文数据库医药卫生科技辑》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111803477A (en) * | 2020-08-11 | 2020-10-23 | 上海交通大学 | The use of disulfiram in the preparation of anti-head and neck cancer and anti-fibrosis drugs |
| CN114146073A (en) * | 2020-09-07 | 2022-03-08 | 上海交通大学医学院 | Application of disulfiram in enhancing immune response |
| CN114146073B (en) * | 2020-09-07 | 2023-08-11 | 上海交通大学医学院 | Use of disulfiram in enhancing immune response |
| CN114366749A (en) * | 2020-10-15 | 2022-04-19 | 中国人民解放军海军军医大学 | Use of integrin inhibitor in preparation of medicament for treating renal cancer |
| CN114366749B (en) * | 2020-10-15 | 2023-06-30 | 中国人民解放军海军军医大学 | Use of integrin inhibitors in the preparation of medicaments for the treatment of renal cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts | |
| WO2015180600A1 (en) | Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same | |
| CN108514639A (en) | It is a kind of to be used for antitumor combination medicine and its preparation and application | |
| CN114288278B (en) | Drug-loaded microalgae, preparation method and application thereof | |
| CN109908143A (en) | New application of Theo Buddhist nun sieve in preparation treatment acute myeloid leukemia drug | |
| Vali et al. | Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer | |
| CA2286557A1 (en) | Phorbol esters as anti-neoplastic agents | |
| CN101612400A (en) | 1 application of receptor antagonist in antitumor of angiotensin | |
| WO2015172712A1 (en) | Pharmaceutical composition for injection with synergistic effect of vitamin c and antitumour drugs | |
| CN108186643B (en) | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof | |
| CN112979753B (en) | A kind of polypeptide targeting c-Met and its application | |
| CN107375258A (en) | A kind of antineoplastic combination medicine and its purposes in cancer therapy drug is prepared | |
| CN103656615B (en) | A kind of HM-3 and platinum class, taxanes or his shore class medicine purposes in preparing solid tumor drugs | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| CN103623394A (en) | Application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines | |
| CN101229175A (en) | Medicinal application of a pair of protopanaxadiol derivatives and their mixture | |
| JP2020045363A (en) | Composition comprising hydrogen gas for suppression or prevention of cancer metastasis | |
| CN104688722B (en) | Purposes of the epimedium aglucone in preparation prevention or treatment bone marrow suppression drug | |
| Devi et al. | Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma | |
| CN101283996B (en) | Application of clock wise D-methionine in preparing the medicine for preventing and curing the myelosuppression induced by radiation | |
| CN106668061B (en) | An anticancer drug composition containing cisplatin | |
| Oyadomari et al. | Evaluation of tumor growth remission in a murine model for subcutaneous solid tumors–Benefits of associating the antitumor agent crotamine with mesoporous nanosilica particles to achieve improved dosing frequency and efficacy | |
| JPWO2014050912A1 (en) | Liquid medicine dissolved with carbon dioxide and therapeutic method using the same | |
| Yuen et al. | High-dose vitamin C helps prevent recurrence of stage IV ovarian cancer: A case report | |
| CN115068615B (en) | A "open source and reduce expenditure" anti-tumor pharmaceutical composition for reversing hypoxia and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180911 |
|
| RJ01 | Rejection of invention patent application after publication |